Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18f-fluorodopamine is a radiopharmaceutical and positron emission tomography (PET) imaging tracer that serves as a fluorine-18 labeled analogue of the neurotransmitter dopamine. It is specifically designed to visualize the sympathetic nervous system and neuroendocrine tissues. Mechanistically, 18f-fluorodopamine acts as a substrate for the norepinephrine transporter (NET), also known as Uptake-1, which facilitates its accumulation into the storage vesicles of sympathetic nerve endings and chromaffin cells. This targeted uptake makes it highly effective for the localization and staging of catecholamine-producing tumors, including pheochromocytomas, paragangliomas, and neuroblastomas. It is frequently compared to the conventional tracer 123I-MIBG, often demonstrating superior image resolution and sensitivity, particularly in the detection of metastatic disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18f-fluorodopamine.